Get the Stockscreener App
2.28
5.56%
0.12
After Hours:
2.30
0.02
+0.88%
Biovie Inc stock is traded at $2.28, with a volume of 1.53M.
It is up +5.56% in the last 24 hours and up +50.00% over the past month.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.
See More
Previous Close:
$2.16
Open:
$2.374
24h Volume:
1.53M
Relative Volume:
0.38
Market Cap:
$19.27M
Revenue:
-
Net Income/Loss:
$-19.92M
P/E Ratio:
-0.5338
EPS:
-4.2716
Net Cash Flow:
$-20.51M
1W Performance:
+6.54%
1M Performance:
+50.00%
6M Performance:
+65.22%
1Y Performance:
+50.00%
1-Day Range:
$2.28
$2.49
1-Week Range:
$1.93
$2.49
52-Week Range:
$0.82
$3.79
Biovie Inc Stock (BIVI) Company Profile
Name
Biovie Inc
Sector
Industry
Phone
775-888-3162
Address
680 W NYE LANE, CARSON CITY
Compare BIVI vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BIVI
Biovie Inc
|
2.28 | 15.72M | 0 | -19.92M | -20.51M | -4.2716 |
VRTX
Vertex Pharmaceuticals Inc
|
544.52 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
799.08 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,031.66 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
140.34 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
205.57 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Biovie Inc Stock (BIVI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-22-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-15-21 | Initiated | B. Riley Securities | Buy |
Biovie Inc Stock (BIVI) Latest News
BIVI Jumps As BioVie Reports Strong Parkinson’s Trial Data - StocksToTrade
BioVie Inc.Warrant (Nasdaq:BIVIW) Stock Quote - FinancialContent
BIVI Stock Pops As SUNRISE-PD Parkinson’s Data Fuel Hype - timothysykes.com
BioVie (BIVI) Jumps As SUNRISE-PD Data Fuel Bullish Hopes - StocksToTrade
Which stocks are moving before the opening bell on Friday? - ChartMill
12 Health Care Stocks Moving In Thursday's Intraday Session - Sahm
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Sahm
BioVie (BIVI) Financial Update: Profit Per Share Surpasses Its Benchmark in Latest Trading; Share Response: Shares Close 38.81% Higher on the DayWeak Earnings Momentum - vinanet.vn
MicroCaps IGC, BIVI, ORBS, RIME Sub-$1 Stocks to Watch Now - Barchart.com
BioVie (BIVI) Revenue BreakdownMain Composition - Moomoo
$BioVie (BIVI.US)$ told yall yesterday - Moomoo
BIVI Stock Draws Trader Focus After Strong Parkinson’s Data - StocksToTrade
BIVI Stock Draws Attention After Strong Parkinson’s Data - StocksToTrade
$BioVie (BIVI.US)$ Ready for lift off - Moomoo
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
New 8.4% BioVie (NASDAQ: BIVI) stake sits entirely in warrants - Stock Titan
BIVI Stock In Focus After SUNRISE-PD Trial Breakthrough - StocksToTrade
BIVI Stock Pops As Parkinson’s Drug Data Fuels Momentum - StocksToTrade
BIVI Stock In Play After Positive Parkinson’s Trial Data - timothysykes.com
Top Premarket Gainers - marketscreener.com
BIVI Q2 2026 Earnings: EPS Beat of 5.99% Offers Little Shelter as Shares Slide 5.56%Operating Income Trends - vinanet.vn
Biovie Stock Price Forecast. Should You Buy BIVI? - StockInvest.us
First Phosphate and BioVie Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV - New Castle News
BioVie Phase 2b Parkinson’s Trial Meets Primary Endpoint - Minichart
BioVie Inc. (BIVI) Holds Steady at $1.56 as Shares Consolidate Between Key Support and ResistanceBollinger Squeeze - vinanet.vn
BioVie Inc. Reports Earnings Results for the Full Year Ended June 30, 2026 - marketscreener.com
These stocks have an unusual volume in today's session - ChartMill
BioVie Q4 Results: EPS loss narrows 51% YoY to $(0.70) - scanx.trade
BIVI Stock Jumps As SUNRISE-PD Data Fuels Parkinson’s Hopes - timothysykes.com
BIOVIE INC. FY 2026: Net loss $22.1M — 10-K Summary - TradingView
Biotech Stocks At 52-Week HighsBIVI +22%, XNCR, ANRO, HAE, ACAD - RTTNews
BioVie Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
BIVI Stock Jumps As SUNRISE-PD Data Fire Up Parkinson’s Hopes - StocksToTrade
BIVI Stock Jumps As SUNRISE-PD Data Ignites Parkinson’s Hopes - timothysykes.com
These stocks are the most active in today's session - ChartMill
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Why BioVie (BIVI) Stock Is Up Today - Quiver Quantitative
BioVie Inc. Warrant (BIVIW) Edges Higher to $0.18, Holding Between Support and ResistanceGamma Squeeze - Vinanet
BioVie Inc. Revenue Breakdown – NASDAQ:BIVIW - TradingView
BioVie Inc (BIVI) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
New to The Street NASDAQ MARKETSITE - ACCESS Newswire
New to The Street Show 766 Broadcasts Tonight at 6:30 PM ET on Bloomberg Television, Featuring BioVie's Bezisterim Parkinson's Disease Clinical Results - Caledonian Record
BioVie Inc. Warrant (BIVIW) Surges 14.29% to $0.16 — Testing Key ResistanceWyckoff Accumulation - vinanet.vn
Morgan Stanley (BIVI) discloses 896,822 BioVie shares, an 11.9% stake - Stock Titan
Morgan Stanley (BIVI) discloses 8.0% beneficial stake in BioVie Class A shares - Stock Titan
BioVie posts corporate presentation outlining bezisterim, BIV201 clinical programs in neurodegeneration, Long COVID, liver disease - Bitget
BioVie Inc (BIVI) Stock News Today - TradingKey
Parkinson's drug developers are betting big on inflammation - Proactive financial news
Join Biovie's Exclusive Live Investor Webinar: Inside the SUNRISE-PD Topline Results - finance.yahoo.com
BioVie stock sinks on Phase IIb Parkinson’s trial data - Yahoo Finance
BioVie Announces Topline Results of Phase 2 SUNRISE-PD Trial of Bezisterim in Early Parkinson’s Disease - markets.businessinsider.com
Biovie Inc Stock (BIVI) Financials Data
Revenue
Net Income
Cash Flow
EPS
Biovie Inc Stock (BIVI) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Chappell Amy Suzon | Director |
Aug 28 '26 |
Buy |
2.16 |
727 |
1,570 |
727 |
| KIM JOANNE WENDY | Chief Financial Officer |
Aug 28 '26 |
Buy |
2.18 |
2,500 |
5,450 |
3,441 |
| DO CUONG V | President & CEO |
Aug 27 '26 |
Buy |
2.08 |
15,210 |
31,637 |
16,117 |
0.46%
2.77%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):